Humphreys Keith 4

What Happened
Keith Humphreys, a director of Indivior Pharmaceuticals, was granted 6,518 Restricted Stock Units (RSUs) on 2026-05-13. The Form 4 reports an acquisition price of $0.00 (typical for RSU awards); no cash was paid. The RSUs are a contingent right to receive one share each and vest on the day immediately preceding the issuer’s next annual meeting, subject to Humphreys’ continued service.

Key Details

• Transaction date: 2026-05-13; Form 4 filed 2026-05-14 (timely filing).
• Transaction type/code: Award/Grant (A). Reported acquisition price: $0.00.
• Shares granted: 6,518 RSUs. Shares owned after the transaction are not specified in the provided summary.
• Footnote: RSUs vest the day before the next annual meeting, conditional on continued service (see F1).
• No sale or open-market purchase occurred — this is compensation, not a market trade.

Context
RSUs are a common form of director compensation and do not represent an immediate sale or purchase; they convert to shares only if/when they vest. The economic value depends on Indivior’s share price at vesting and may dilute existing holders when settled. Awards like this are routine and, by themselves, don’t necessarily signal insider sentiment about the stock.